DTR - Post-transplant Considerations: De Novo Malignancies in LT Recipients & Presidential Address
About
Review and discuss research regarding non-hepatic malignancy in the candidate, the donor or the recipient, including selection criteria/indications, prognostic models, surveillance strategies, novel therapies and management.
Gain insight into innovations that lead to improvement in the field of liver transplantation in candidates or donors with a history of malignancy, and in recipients with de novo cancer, both in adult and pediatric populations.
When
Wednesday, January 20, 2021 · 12:00 p.m.
Berlin (GMT +1:00)
WEBINAR ENDED
Agenda
Incidence and risk factors - Kymberly Watt, MD
Screening strategies after liver transplantation - José Ignacio Herrero, MD
Treatment for solid tumors - Gonzalo Sapisochin, MD
Treatment for post-transplant lymphoproliferative disorders (PTLD) - Dok Hyun Yoon, MD
Q&A
Presidential address - Claus Niemann, MD
Presenters
Gonzalo Crespo, MD
Moderator
Hospital Clinic de Barcelona, Barcelona, Spain
Mark Ghobrial, MD, PhD, FRCS
Moderator
Houston Methodist Hospital, Houston, USA
Kymberly Watt, MD
Speaker
Mayo Clinic, Rochester, USA
José Ignacio Herrero, MD
Speaker
University Clinic of Navarra, Pamplona, Spain
Gonzalo Sapisochin, MD
Speaker
UHN - Toronto General Hospital, Toronto, Canada
Dok Hyun Yoon, MD
Speaker
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea